Entered into a definitive merger agreement with Day One Biopharmaceuticals, Inc. on November 12, 2025, for $25.00 per share in cash plus contingent value rights up to $30.25 per share, totaling up to $285 million, with closing expected by end of January 2026.
Strategic restructuring in May 2025 reduced workforce by 55%, eliminated internal pipeline development, and focused R&D on breast cancer for lead candidate Emi-Le.
Ongoing clinical trials for lead candidates Emi-Le (B7-H4-targeting/XMT-1660) and XMT-2056, with encouraging interim data and resumed enrollment after FDA hold lifted.
Achieved a $15 million milestone payment from GSK for XMT-2056 development in Q3 2025; collaborations with Johnson & Johnson and Merck KGaA progressing.
Collaboration revenue for Q3 2025 was $11.0 million, down from $12.6 million in Q3 2024; nine-month revenue was $16.8 million, down from $24.1 million year-over-year.
Net loss for Q3 2025 was $7.5 million ($1.51 per share), improved from $11.5 million ($2.34 per share) in Q3 2024; nine-month net loss was $56.0 million.
Cash and cash equivalents as of September 30, 2025, were $56.4 million, with capital resources expected to last into mid-2026.
Operating expenses and R&D expenses decreased year-over-year due to restructuring; R&D expense for Q3 2025 was $12.2 million.
Fully repaid $25 million in debt in July 2025, resulting in a $0.4 million loss on extinguishment.
Current cash expected to fund operations into mid-2026; substantial doubt exists about ability to continue as a going concern if the merger is not completed.
Future funding needs may require additional equity, debt, or strategic transactions if acquisition does not close.
Focused near-term development on Emi-Le in breast cancer and continued dose escalation for XMT-2056.
Closing of the acquisition by Day One Biopharmaceuticals anticipated by end of January 2026, pending regulatory and shareholder approvals.
AI chat
)
Automations
)
)
Live audio & transcripts
)
)
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)